Skip to main content

Fiscal Wizard · Single-issue tearsheet

BIIB / Oct 1, 2026 Run #19208
Paper trade

BIIB

Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Composite verdict

B 66.5 / 100
Bullish setup · Reversal 9 drivers · 3 gates blocking
  • Fibonacci Retracement
  • Volume Climax
  • ADX DI Cross
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 4th of 10 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 19 signals0% Bear
Momentum Bullish 100Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 88 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -41%
Asset value $123.56Earnings power value $155.26Price $222.82

Priced above its no-growth earnings power value ($155.26/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

33.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Gross Margin 86
Margin of Safety 0
Capex to Sales 77
OCF to Net Income 0
EV/FCF 76
EPS Growth (YoY) 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Fibonacci Retracement, Volume Climax, ADX DI Cross); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Fibonacci Retracement 84
Vortex Signal 83
Volume Climax 82

Risk Gates

3 blocking 3 caution

3 guards active, 23 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Interest Coverage Caution

Weak interest coverage blocks bullish signals — debt-service risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BIIB.